Verapamil Hydrochloride Nanosuspension and Assessment of Cardioprotective effect in Experimental Model of Myocardial Infarcted Rats
Main Article Content
Abstract
Aim and Objective: Verapamil, a calcium channel blocker, has a restricted bioavailability (20–30%) due to
substantial hepatic first-pass degradation. Therefore, the main goal of this work was to use nanosuspension with
high shear homogenization and ultrasonication techniques to improve the oral bioavailability of verapamil. Method:
Animals used in experiments were given a myocardial infarction. Verapamil nanosuspension was used in an in
vivo pharmacological investigation and to evaluate cardiac damage indicators. Results: When compared to free
medications, in vivo pharmacokinetic studies showed greater t1/2, area under the curve from zero to infinity, and Cmax
, suggesting improved bioavailability. Oral verapamil nanosuspension treatment improved nearly all hemodynamic
parameters studied in the isoproterenol induced myocardial necrosis model, including cardiac damage indicators
and left ventricular end-diastolic pressure. Conclusion: These positive outcomes highlight the created verapamil
nanosuspension’s excellent oral administration capabilities, which may enhance the therapeutic effect.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.